Overall | HIV-infected MSM | HIV-uninfected MSM | ||||
Rate* | 95% CI | Rate* | 95% CI | Rate* | 95% CI | |
Any HPV | ||||||
Incidence | 17.8 | 12.4 to 25.4 | 21.2 | 13.0 to 34.7 | 15.0 | 9.0 to 25.2 |
Clearance | 87.1 | 64.4 to 117.8 | 82.8 | 54.3 to 126.5 | 92.8 | 60.3 to 142.8 |
High-risk HPV | ||||||
Incidence | 8.3 | 5.1 to 13.4 | 10.7 | 5.5 to 20.8 | 6.5 | 3.2 to 13.3 |
Clearance | 98.4 | 65.7 to 147.5 | 121.1 | 67.7 to 216.8 | 82.7 | 46.6 to 146.8 |
HPV16 | ||||||
Incidence | 2.0 | 0.8 to 4.9 | 0.8 | 0.1 to 5.4 | 3.2 | 1.2 to 8.9 |
Clearance | 80.9 | 41.9 to 156.2 | 44.8 | 11.2 to 179.3 | 105.5 | 49.6 to 224.2 |
HPV33 | ||||||
Incidence | 1.0 | 0.3 to 3.2 | 1.5 | 0.4 to 6.4 | 0.6 | 0.1 to 4.3 |
Clearance | 34.7 | 8.7 to 138.3 | 53.1 | 7.6 to 373.3 | 25.7 | 3.6 to 182.0 |
HPV39 | ||||||
Incidence | 1.1 | 0.3 to 3.6 | 0.7 | 0.1 to 5.4 | 1.7 | 0.4 to 8.1 |
Clearance | 67.9 | 16.9 to 273.1 | 44.4 | 6.2 to 319.2 | 137.7 | 19.4 to 976.7 |
HPV51 | ||||||
Incidence | 0.9 | 0.2 to 4.1 | n.e. | n.e. | ||
Cearance | 144.9 | 44.3 to 474.7 | n.e. | n.e. | ||
HPV56 | ||||||
Incidence | 0.6 | 0.1 to 4.8 | n.e. | 1.1 | 0.1 to 9.0 | |
Clearance | 233.5 | 52.9 to 1030.0 | n.e. | 232.9 | 52.6 to 1031.7 | |
HPV58 | ||||||
Incidence | n.e. | n.e. | n.e. | |||
Clearance | 99.0 | 13.4 to 731.3 | n.e. | n.e. | ||
HPV59 | ||||||
Incidence | 0.4 | 0.05 to 2.8 | 0.8 | 0.1 to 5.7 | n.e. | |
Clearance | 80.0 | 25.6 to 250.0 | 57.7 | 14.4 to 231.3 | n.e. | |
HPV66 | ||||||
Incidence | 3.0 | 1.1 to 8.5 | n.e. | 1.4 | 0.3 to 6.2 | |
Clearance | 245.2 | 97.4 to 617.3 | n.e. | 78.7 | 11.3 to 549.0 | |
HPV68 | ||||||
Incidence | 1.6 | 0.5 to 5.7 | n.e. | 0.8 | 0.1 to 6.2 | |
Clearance | 205.9 | 76.8 to 552.1 | n.e. | 128.2 | 31.3 to 524.2 |
High-risk genotypes for which neither incidence nor clearance could be estimated because zero transitions are not shown.
*Rate is given ×1000 person-months.
HPV, human papillomavirus; MSM, men who have sex with men; n.e., not estimable.